Overlevelsen ved 1, 2 og 3 år var henholdsvis 74, 1%, 51, 2% og 28, 4% for Caelyx sammenlignet med henholdsvis 66, 2%, 31, 0% og 17, 5% for topotecan.
The survival rates at 1, 2 and 3 years were 74.1%, 51.2% and 28.4% respectively on Caelyx, compared to 66.2%, 31.0% and 17.5% on topotecan.